ArticleMolecular therapy. Nucleic acids2025
Generative artificial intelligence, integrative bioinformatics, and single-cell analysis reveal Alzheimer's genetic and immune landscape.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Global prediction of antimicrobial resistance burden and trends using machine learning, deep learning, and GenAI.Annals of medicine and surgery (2012) · 2026Article
- Agentic AI scientists and the rise of virtual laboratories.Annals of medicine and surgery (2012) · 2026Article
- Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease.Molecular therapy. Nucleic acids · 2026Article
- Prompt engineering-enabled GenAI tools to map the landscape of crosstalk within the gut-brain axis (GBA) and its associated factors.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The research aims to understand Alzheimer's genetic and immune landscapes using the amalgamation of three technologies: artificial intelligence (GenAI), integrative bioinformatics, and single-cell analysis. First, the study aims to identify and characterize the significant genes associated with Alzheimer's disease (AD) using three GenAI models (GPT‑4o, Gemini model, and DeepSeek). After the genes were accumulated from GenAI models, 27 genes associated with AD were recoded. Furthermore, they were analyzed using integrative bioinformatics methods. Similarly, the immune landscape of AD using single-cell analysis was also explored, which reveals a high percentage of effector CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.